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DOWN THE DRAIN: PHARMACEUTICAL WASTE
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Toby K. L. Morgan*
INTRODUCTION

Annually, millions of pounds of unused pharmaceuticals are
flushed down the drain.' As a result, mood stabilizers, antibiotics, sex
hormones and various other pharmaceuticals lurk in the drinking
2
water supplies of individuals across the nation. Recently, interest in
pharmaceutical waste disposal is gaining momentum as scientists
discover mutations in aquatic life resulting from low-level exposure
to pharmaceutical compounds.3 Now, legislators and citizens begin to
* B.A., College of William & Mary, 2006. J.D., William & Mary Law,
2010. I would like to thank my mother for her unwavering support and
encouragement, my friends and family for their faith in me, and Enrique Alonso
Garcia for his inspiration. Finally, I wish to acknowledge Professors Ron
Rosenberg and Rene Bowditch without whom this publication would not have
come to fruition.
1. See Jeff Donn, et al., Health FacilitiesFlush Estimated250M Pounds of
Drugs a YearUSATODAY (Sept. 14, 2008, 12:00 PM), http://www.usatoday.com/
news/health/2008-09-14-drugs-flush-water _N.htm [hereinafter Health Facilities
Flush Estimated250M Pounds of Drugs a Years]. See also Jeff Donn, et al.,
PharmaceuticalsLurking in U.S. Drinking Water, AP ProbeFoundTraces of Meds
in Water Supplies of 41 Million Americans, MSNBC.CoM (Mar. 10, 2008, 11:06
AM), http://www.msnbc.msn.com/id/23503485/ns/health-health care [hereinafter
Pharmaceuticalslurking in U.S. drinking water]; Joseph J. Wang, Unopened,
Unused PrescriptionDrugs Destroyedat Taxpayer Expense, HEALTH LAW &
POL'Y INST. (Nov. 29, 2000), https://www.law.uh.edu/healthlaw/
perspectives/Food/001129Unopened.html.
2. See Health FacilitiesFlush Estimated250M Pounds of Drugs a Year, supra
note 1; see also PharmaceuticalsLurking in U.S. Drinking Water, supra note 1; see
also discussion infra Part I, Section 5.
3. Peter P. Fong, Zebra Mussel Spawning is Induced in Low Concentrationsof
Putative Serotonin Reuptake Inhibitors, 194 BIOLOGICAL BULL. 143, 143-44 (1998)
(finding that serotonin reuptake inhibitors, such as Paxil, which are used by humans
for the treatment of depression, obesity, and even convulsive seizures, can effect

393

394

FORDHAMENVIRONMENTAL LA WREVIEW

[VOL. XXII

wonder whether long-term exposure to pharmaceuticals and personal
care products ("PPCP"), in similar dosages, may pose a significant
risk to human health as well. 4
The term "PPCP" was developed quite recently.5 Nevertheless,
each year, as more scientific research and data is collected, PPCPs
become more of an important issue. Even in low concentrations, the
presence of pharmaceutical waste in our waterways has resulted in
environmental transformations and variations. As pharmaceutical
waste continues to mount it begs the question: is it possible that what
we cannot see in our waterways is equally if not more harmful than
what we can?
PPCPs are engineered to interact with the environment by
stimulating "a physiological response in humans, plants, and
animals."6 Understanding how PPCPs continue to affect plants,
animals, humans, and other earth systems after disposal is perhaps
one of the most difficult environmental problems science and the law
face today. Significant advances in research and a change in
regulation are needed if we are to reduce the presence of PPCPs in
the nation's waste, surface and drinking water.
This Note is an introduction to pharmaceutical waste disposal and
regulation in the United States. The very nature of the PPCP waste
issue requires synergy between legislators and the scientific
community, as adequate regulation must reflect and counteract the
potential implications of low-dose exposure to humans, plants and
animals. Perhaps, if adequately handled, it is not too late to correct
invertebrates when they are exposed to low concentrations specifically, inducing
spawning in male and female zebra mussels).
4. See PharmaceuticalsLurking in U.S. Drinking Water, supra note 1. But cf
PHILLIP SCHABECOFF & ALICE SCHABECOFF, POISONED PROFITS: THE Toxic
ASSAULT ON OUR CHILDREN 99 (2008) (finding that the anti-depressant, Paxil, "is
effective at 30 parts per billion, and the chemical in birth control pills" is effective
"at 0.019" parts per billion (ppb)).

5. See Christian G. Daughton, Cradle-to-Cradle Stewardship of Drugs for
Minimizing Their Environmental Disposition While Promoting Human Health. I.
Rationalefor andAvenues Toward a Green Pharmacy, 111 ENVTL. HEALTH PERSP.
775, 775 (2003); see also ENVTL. PROT. AGENCY, PHARMACEUTICALS AND
PERSONAL
CARE
PRODUCTS
(PPCPs),
http://www.epa.gov/ppcp/basic2.html.

BASIC

INFORMATION

(2010),

6. See Dana Kolpin et al., Pharmaceuticals,Hormones, and Other Organic
Wastewater Contaminants in US. Streams, 1999-2000: A National
Reconnaissance, 36 ENVTL. Sci. & TECH. 1202, 1202 (2002).
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the mistakes that a history lacking in effective PPCP research and
regulation has failed to address.
Part I introduces PPCPs by discussing PPCP research
developments within the past decade, while paying close attention to
the current PPCP regulatory framework. Part II addresses the impact
of the Environmental Protection Agency's ("EPA") Proposed
Universal Waste Amendment ("UWA"), which seeks to add
pharmaceutical waste to the universal waste regulatory framework.
The EPA's proposals, if adopted, will allow generators of
pharmaceutical waste to either continue current pharmaceutical
disposal methods to conform with the Resource Conservation and
Recovery Act ("RCRA") or begin regulation under the Universal
Waste Rule ("UWR"). Part III discusses the burden placed on
pharmaceutical waste generators, the privatization of the
pharmaceutical waste disposal regime, and the regulatory quandary
created by an overlap in federal, state and local legislation. Part III
concludes with a review of current proposals that emphasize the
important role consumers play in combating PPCP exposure.
I. PART I
A. Chemical Pollution and its Role in the Development ofPPCP
Specific Research
For several decades, before the EPA began conducting PPCP
specific research in the 1990's, scientists were concerned that
national widespread chemical use could create adverse health
effects.7 This concern spawned further research in the area of
chemical pollution and subsequently led to PPCP-specific research.
Initially, the chemicals investigated included those widely used in the
7. See generally RACHEL CARSON, SILENT SPRING 15 (1962); PRISCILLA COIT
MURPHY, WHAT A BOOK CAN Do: THE PUBLICATION AND RECEPTION OF SILENT
SPRING 1, 159 (2005); MARK H. LYTLE, THE GENTLE SUBVERSIVE: RACHEL
CARSON, SILENT SPRING, AND THE RISE OF THE ENVIRONMENTAL MOVEMENT 133

(2007); Thirty Years After Silent Spring: Status of EPA's Review of Older
Pesticides: Hearing Before the Environment, Energy, and Natural Resources
Subcomm. of the Comm. on Government Operations H.R., 102nd Cong. 1-4 (1992)
(Rachel Carson's book discussing pesticides and their effect on bird species
launched much of the early chemical pollution research).
8. See SCHABECOFF & SCHABECOFF, supra note 4, at 207-08; Daughton, supra

note 5, at 757; Kolpin et al., supra note 6, at 1202.
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farming and medical industry, but eventually expanded to include the
chemical compounds commonly found in pharmaceuticals and
household products as well. 9 Now, in light of this research, scientists
confirm that many of these chemicals act as contaminants, traveling
via a vast number of disposal pathways, slowly dispersing into and
amalgamating with the environment.' 0
Certain chemical contaminants, such as pesticides, are deliberately
disseminated into the environment, admittedly in quantifiable
amountsI1 while other contaminants, such as industrial byproducts,
often enter water resources by uncontrolled means.12 Veterinary
pharmaceuticals also inadvertently enter the environment by the
"overflow or leakage" of animal waste storage vats.1 3
The nature of these chemical contaminants allows them to persist
in the environment for much longer than initially anticipated.14
"Household chemicals, pharmaceuticals, and other consumables as
well as biogenic hormones" still persist in the environment, even
after enduring wastewater treatment, because the treatment process
cannot remove these compounds from the effluent at the low
concentration levels that are present in our waterways.' 5 Today,
knowledge of these disposal pathways plays an important role in
determinations made by legislators and regulators concerning
pharmaceutical waste management in facilities and households across
the nation.

9. See Kolpin et al., supra note 6, at 1202.
10. See id.
11. See id.
12. See id. A multitude of chemical compounds are distributed into the
environment on a daily basis as a result of persistent industrial use. Trying to
exhaustively list these chemicals is virtually impossible. For instance, try to
imagine the amount of chemicals used to clean and maintain an industrial building
and its infrastructure then multiply that use throughout a city, county, state, then
nationwide. These contaminants are "industrial byproducts." They enter our water
systems by "uncontrolled means" because these contaminants can enter waterways
through rainwater runoff or through the sewer system if wastewater containing
cleaning products is flushed, for example. Id.
13. See id.
14. See id.
15. See id.
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B. The Beginning ofPPCPSpecific Research

In December of 1999, a critical review of PPCPs in the
environment entitled "Pharmaceuticals and Personal Care Products in
the Environment: Agents of Subtle Change?" ("PPCPs in the
Environment") was published.16 This study synthesizes the research
and data available concerning PPCPs.17 PPCPs encompass
"pharmaceutical, veterinary, and illicit drugs, the ingredients in
cosmetics, food supplements, and other personal care products,"
"together with their respective metabolites and transformation
products."' More detailed research on PPCPS eventually developed,
but this study was one of the first to address, define and legitimize the
issue. 19 The study aided in the development of additional PPCP
specific research and would lead to more definitive determinations of
the risks that PPCPs pose to the environment. 20
Enumerating the chemical groups that fall under the PPCP purview
was one of the easier tasks, while attempting to determine and
regulate the environmental impact of PPCPs is a more difficult
hurdle. 2 Just as researchers uncovered while conducting contaminant
research in previous decades, PPCPs are also used and dispensed of
in a variety of ways across the nation.22 Because PPCPs primarily
enter the environment as the effluent of sewage treatment works
("STW") and via terrestrial run-off, researchers discovered that a
large percentage of commercially used PPCPs are ubiquitous and
continuously persist in the environment.2 3
At the time of "PPCPs in the Environment" publication in 1999,
occurrence data was only available for fifty nonantibiotic drugs
gathered using aquatic monitoring systems that could not detect
16. Christian G. Daughton & Thomas A. Ternes, Pharmaceuticalsand Personal
Care Products in the Environment: Agents of Subtle Change?, 107 ENVTL. HEALTH
PERSP. 907 (1999).
17. See id.
18. Id. at 908.
19. See MARC J. ZIMMERMAN, U.S. GEOLOGICAL SURV., OCCURRENCE OF
ORGANIC WASTEWATER CONTAMINANTS, PHARMACEUTICALS, AND PERSONAL
CARE PRODUCTS IN SELECTED WATER SUPPLIES, CAPE COD, MASSACHUSETTS,

JUNE 2004 2 (2005), http://pubs.usgs.gov/of/2005/1206/pdflofr2005
20. Id.
21. See Daughton,supra note 16, at 934.

22. See id. at 907.
23. See id.

1206.pdf.
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PPCPs at the low concentration levels found in the environment. 24
Today, not much has changed. Very few pharmaceutical
contaminants have been adequately studied, leaving the thousands
more that are currently approved for use without accurate occurrence
data.25 Equipped with limited available data, scientists eventually
demonstrated that PPCPs can have a devastating effect on aquatic
life, even in low concentrations. 26 Unfortunately, because this is such
a burgeoning issue, the long-term effects that these chemicals may
have on humans and the environment will remain unknown for
decades to come. Researchers are battling chemicals that are
continuously infused back into the environment and are attempting to
pinpoint, or even predict, the longevity and persistence of these
chemical contaminants in the environment. 2 8
C. Recent Developments in PPCPResearch
In March of 2002 the United States Geological Survey ("USGS")
released the results of a national reconnaissance on the occurrence of
pharmaceuticals in surface waters.29 The USGS reconnaissance
studied various "antibiotics, prescription drugs, nonprescription
drugs, steroids, [and] reproductive hormones." 30 The research also
addressed other contaminants such as "personal care products,
products of oil use and combustion, and other extensively used
chemicals." 3 1
Even after nearly five years, the USGS only had the ability to
assess the environmental occurrence of ninety-five organic
wastewater contaminants ("OWC"), not a far cry from the fifty
pharmaceuticals that had been studied when "PPCPs in the
Environment" was released in 1999.32 Astonishingly, of the 139
streams across thirty states surveyed by the USGS, one or more of the
ninety-five contaminants tested for were found in 80% of the

24.
25.
26.
27.
28.
29.
30.
31.
32.

See id. at 909.
See id.
See id. at 909-10.
See Daughton, supra note 16, at 908.
See id. at 908, 922-23.
Kolpin et al., supra note 6, at 1202.
Id. at 1203.
Id.
See id.
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samples, with a median of seven contaminants found per stream. 33
The USGS' results proved that pharmaceutical compounds do
"survive wastewater treatment and biodegradation." 34
However, these results only leave scientists with more questions.
What impact can pharmaceutical compounds that are immersed with
a variety of other chemical compounds have on the structure of the
chemical?35 Is it possible that "chemical combinations can exhibit
additive or synergistic toxic effects?" 36 While technology and
research take time to develop answers, legislators turn their attention
toward determining how these pharmaceutical pollutants enter the
environment.
D. How PharmaceuticalsEnter the Environment

As discussed above, one of the key problems scientists and
regulators face when addressing pharmaceutical waste management
is determining the pervasiveness of these contaminants and
ascertaining how they enter the environment. 37 Notwithstanding the
issue of various non-point sources of entry, such as run-off and
atmospheric cycling, the task of identifying how these contaminants
enter the environment, even from discernable point sources such as
STWs and incinerators, continues to be particularly burdensome. 38
Consequently, in order to effectively formulate regulation, it is
important to first determine how pharmaceutical waste is disposed of
and managed.
Today, many pharmaceutical waste generators fail to properly
distinguish between hazardous pharmaceutical waste, hazardous solid
33. Kolpin et al., supra note 6, at 1208-10. Interestingly, contaminants such as
nonprescription drugs were detected at a much higher frequency than antibiotics
and prescriptions. See id. at 1209.
34. Id. at 1210.
35. Currently, these pharmaceutical compounds are rarely found in isolation and
their presenve is usually documented in tandem with other contaminants. See, Dana
W. Kolpin, Jack E. Barbash & Robert J. Gilliom, Pesticides in Ground Water of
United States, 1992-1996, 38 GROUND WATER 858, 858-61 (2000); Kolpin et al.,
supra note 6, at 1210.
36. See Kolpin et al., supra note 6, at 1210.
37. See Despo Fatta-Kassinos et al., PharmaceuticalResidues in Environmental
Waters and Wastewater: Current State of Knowledge and Future Research, 399
ANALYTICAL & BIOANALYTICAL CHEMISTRY 251, 272 (2010).

38. Id. at 252, 254.
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waste, and other non-hazardous waste 39 or are simply unaware of
federal reporting requirements. 40 As a result, the information that
stems from what are, in many ways, quantifiable and defined
pharmaceutical waste streams remains askew due to ignorance or
neglect on the part of generators when implementing federal
pharmaceutical waste disposal guidelines.4 1
Below, a brief synopsis of various pharmaceutical waste generation
and disposal studies provides a rough outline of the quantity of
pharmaceutical waste disposed of nationally. Although each survey
is a small representation of how pharmaceutical waste enters the
environment, the studies, when analyzed in tandem, reflect the
amount of pharmaceutical waste released annually in the United
States. This section also discusses how pharmaceutical waste
disposal is currently regulated.
1. Hazardous Pharmaceutical Waste: Large Quantity Generators in
the United States
The EPA conducted a cost benefit analysis for its proposal to
amend the UWA relying heavily on data found in the EPA's National
Biennial Report database ("BRS"). 42 This database includes data
collected by the EPA from facilities defined as large-quantity
generators ("LQG"s) under the RCRA framework.4 3 The EPA
extrapolated the data from the BRS and used that information to
estimate the quantity of pharmaceutical waste disposed of by
39. See ECON., METHODS, & RISK ANALYSIS Div., OFF. OF SOLID WASTE,
ENVTL. PROT. AGENCY, ASSESSMENT OF THE POTENTIAL COSTS, BENEFITS, AND
OTHER IMPACTS OF ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE,
ADDING
AS PROPOSED ES-I (2008) (on file with author) [hereinafter
PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE].
40. See id.
41. See id.; see also Debra Oliver & Alice Chapman, Local Hazardous Waste
Management Program in Kings County, Final Report, Pharmaceutical Waste
Survey, LOCAL HAZARDOUS WASTE MGMT. PROGRAM IN KING CNTY. 16 (2003),

http://www.govlink.org/hazwaste/publications/PharmaceuticalWasteSurvey.pdf
42. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at 7.
43. It should be noted that LQGs are only one of three classes of RCRA
hazardous waste generators and that RCRA hazardous waste does not include all
pharmaceuticals. As such, there are a large number of facilities and
pharmaceuticals that are not considered in this analysis. See discussion infra Part I,
F (for the definition of a LQG).
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hospitals across the nation. 44 The EPA found that hospitals dispose of
9,700 tons of hazardous pharmaceutical waste annually. 45
2. Pharmaceutical Waste: Multiple Source Points
The Local Hazardous Waste Program in King County, Washington
gathered data on the amount of pharmaceutical waste generated in
Washington State.46 The report analyzed ninety-nine businesses that
were potential disposers of pharmaceutical waste.47 This survey
differs from the BRS because it addressed pharmaceutical waste
specifically, not just RCRA hazardous waste, 4 8 and also included data
from small quantity generators ("SQG").49 The survey found that
approximately 1,008,395 pounds of pharmaceutical waste is
disposed" of annually in Washington State alone.
3. Pharmaceutical Waste: STWs
Pharmaceutical waste disposed of by coroner offices can be
extrapolated to quantify the amount of pharmaceutical waste entering
the environment through STWs.5 2 A study conducted with the help of

44.

See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at 10.
45. See Id. "This number does not include data from Michigan or Florida as
they already include hazardous pharmaceutical waste in their universal waste
programs." Id.
46. See Oliver & Chapman, supra note 41, at 2.
47. Id. at 6. The study looked to veterinary clinics, hospitals, doctors' offices,
specialty outpatient facilities, pharmacies, nursing homes etc. Id
48. See Resource Conservation and Recovery Act, 42 U.S.C. § 6903(5)(a)(b)
(2006). RCRA hazardous waste is any solid waste that may "cause, or significantly
contribute to an increase in mortality or an increase in serious irreversible, or
incapacitating reversible, illness; or pose a substantial present or potential hazard to
human health or the environment when improperly treated, stored, transported, or
disposed of, or otherwise managed." Id. While some pharmaceutical waste is
RCRA hazardous, not all RCRA hazardous waste is a pharmaceutical.
49. See id.; see also discussion infra Part 1, F (providing a definition of a SQG).
50. Id. at 20. Disposal methods were vast including flushing, placement in the
household trash, the use of bio-hazardous containers, reverse distribution, recycling
etc. See id. at 14.
51. See id at 20.
52. It is important to note that the coroner disposal data is representative of only
one of many introduction methods for pharmaceutical wastes to enter STWs.
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the Clark County's Coroner Office's did just that by methodically
examining how coroner offices dispose of unwanted pharmaceutical

drugs. 53
Most coroner offices require the collection of drugs at the scene of
a crime, as medication may have contributed to the cause of death or
serve as evidence of a crime. 54 As a result, coroners and other
investigatory staff must dispose of unwanted pharmaceutical waste
once the investigation has been concluded.
Additional sources include, but are not limited to, excretion, bathing, and
household disposal through flushing, et cetera.
53. Christian G. Daughton & Ilene S. Ruhoy, Types and Quantities of Leftover
Drugs Entering the Environment Via Disposal to Sewage - Revealed by Coroner
Records, 388 SCI. OF THE TOTAL ENV'T 137, 137, 143-44 (2007), available at
http://www.epa.gov/esdibios/daughton/SOTE2007.pdf.
54. Id. at 141.
55. Id. Under the Controlled Substances Act ("CSA"), once an individual has
been prescribed a drug, he is prohibited from allowing anyone else to take
possession of the drug on his behalf, save a law enforcement official. As a result,
all pharmaceuticals identified by investigating officials at a crime scene must be
taken into possession by law enforcement officers. See id. Currently, the CSA
allows individuals to dispose of unwanted drugs as they see fit. See Disposal of
Controlled Substances, 21 C.F.R. § 1307.21(b)(4) (2009). The FDA advises that
individuals "follow any specific disposal instructions on the drug label. . ."
CONSUMER HEALTH INFO., U.S. FOOD & DRUG ADMIN., How To DISPOSE OF
UNUSED MEDICINES, 1 (2011) available at http://www.fda.gov/downloads/Drugs/
ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingOverthe-CounterMedicines/ucm107163.pdf. The following drugs recommend flushing
as the preferred method of disposal: "Actiq, oral transmucosal lozenge, Fentanyl
Citrate, Avinza capsules (extended release), Morphine Sulfate, Daytrana,
transdermal patch system, Methylphenidate, Demerol, tablets, Meperidine
Hydrochloride, Demerol oral solution, Meperidine Hydrochloride, Diastat/Diastat
AcuDial rectal gel, Diazepam, Dilaudid tablets, Hydromorphone Hydrochloride,
Dilaudid oral liquid, Hydromorphone Hydrochloride, Dolophine Hydrochloride
tablets, Methadone Hydrochloride, Duragesic patch (extended release), Fentanyl,
Embeda capsules (extended release), Morphine Sulfate; Naltrexone Hydrochloride,
Exalgo tablets (extended release), Hydromorphone Hydrochloride, Fentora tablets
(buccal), Fentanyl Citrate, Kadian capsules (extended release), Morphine Sulfate,
Methadone, Hydrochloride oral solution, Methadone Hydrochloride, Methadose
tablets, Methadone Hydrochloride, Morphine Sulfate tablets (immediate release),
Morphine Sulfate, Morphine Sulfate oral solution, Morphine Sulfate, MS Contin
tablets (extended release), Morphine Sulfate, Onsolis soluble film (buccal),
Fentanyl Citrate, Opana tablets (immediate release), Oxymorphone Hydrochloride,
Opana ER tablets (extended release), Oxymorphone Hydrochlorid." U.S. FOOD &
DRUG ADMIN., DISPOSAL OF UNUSED MEDICINES: WHAT YOU SHOULD KNow
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The study uncovered that of the pharmaceuticals collected at crime
scenes over 92% were flushed 56 while approximately 7% of other
medications were disposed of in the trash. 57 In all, less than 1%of the
pharmaceutical waste collected was incinerated and usually only
incinerated when the drugs were unidentifiable.
The researchers also found that 325,000 pharmaceuticals were
discarded into the STWs of Clark County, Nevada,5 9 amounting to
over 224 pounds of pharmaceutical waste.60 Due to the similarities
between the death rates in Nevada and the rest of the country,
researchers conducting the study extrapolated the data to estimate
that 17.9 tons of pharmaceutical waste enters STWs annually across

the nation.61
4. Pharmaceutical Waste: Drinking Water
In March 2008, the Associated Press ("AP") investigated the
presence of pharmaceuticals in drinking water across the nation.62
The investigation relied on scientific reports, federal drinking water
databases, and interviews with more than 230 officials, academics
and scientists.63 The AP surveyed major water providers in the
nation's fifty largest cities and also surveyed smaller water providers
in all states.64 Over the course of five months, the AP detected

(2011) (list revised Mar., 2010) availableat
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/
BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicin
es/ucml86187.htm#MEDICINES.
56. Daughton & Ruhoy, supra note 53, at 144.
57. Id. at 144-45.
58. Id. at 145.
59. See Id. at 145. It is important to note that other medical waste, such as
powders, liquids, "inhalers, patches, and syringes" were not quantified in the study
even though powders and liquids were flushed (the other items were thrown away
in the household trash). Id.
60. Id.
6 1. Id.
62. US Water (AP Television broadcast Mar. 10, 2008) (transcript on file with
the Associated Press Archive), availableat http://www.aparchive.com/
Search.aspx?remem=x&st-k&kw-drinking+water#mainActionMenu.
63. See PharmaceuticalsLurking in U.S. Drinking Water, supra note 1.
64. See id; see also US Water, supra note, 62. The television broadcast notes
that several water providers were reluctant to disclose the results of the
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pharmaceuticals, including "antibiotics, anti-convulsants, mood
stabilizers and sex hormones," in the drinking water of forty-one
million residents.6 5
E. PPCP Effects
The environmental and physical effects of PPCP contaminants
have long remained a mystery.66 However, in recent decades, studies
have uncovered some of PPCPs' adverse effects on biological and
aquatic life. 67 As discussed above, the USGS reconnaissance6 8
uncovered that pharmaceutical waste contaminants could create
"abnormal physiological processes and reproductive impairment,
increased incidences of cancer, the development of antibioticresistant bacteria, and the potential increased toxicity of chemical
mixtures. ,,69
Today we find that this hypothesis might be accurate. In certain
countries, the human male sperm count has dropped by fifty

pharmaceutical probe because the "public might be unduly alarmed if informed."
Id.
65. US Water, supra note 62. Key test results obtained by the AP: (1) Fish
exposed to contaminants found in wastewater have "reduced testicular growth,
reduced sperm quality and altered hormone ratios." (2) "Steroids, narcotics and
birth control" medications were found in Lake Mead, one of the largest reservoirs
in the world, which provides drinking water to residents in Arizona, California, and
Nevada. (3) Small amounts of medication can cause "human embryonic kidney
cells" to grow too slowly, human blood cells to become inflamed and can allow
breast cancer cells to "proliferate too quickly." (4) In New York, trace amounts of
more than fifteen drugs were found in drinking water. (5) Fish exposed to
pharmaceuticals in wastewater show marked reduction in "testicular growth,"
"sperm quality" and an alteration in "hormone ratios." (6) More than 100 different
pharmaceuticals have been detected in the waters on every continent including the
Swiss lakes and the North Sea. (7) Hormones, antibiotics and other drugs were
found in samples drawn from aquifers in twenty-four states. This information is
particularly alarming as forty percent of the national water supply is sourced from
aquifers. Id.
66. See Daughton & Temes, supra note 16, at 908.
67. See CAROLYN J. OBLINGER ET AL., U.S. GEOLOGICAL SURV., OCCURRENCE
OF PHARMACEUTICALS, PERSONAL-CARE PRODUCTS, OWCS, AND PESTICIDES IN
THE LOWER TALLAPOOSA RIVER '2 (2007), http://pubs.usgs.gov/sir/2007/5266/

pdf/sir2007-5266.pdf.
68. See Kolpin et al., supra note 6, at 1202.
69. Id.
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percent. 70 There have also been increases in hormone-related cancers
and endometriosis. 7 1 Additionally, the impact on aquatic life is
remarkable. Scientists "have found fish laden with estrogen and
antidepressants" facing significant neurological and physiological
changes. 72 A study in Maryland found that certain sea bass produced
both sperm and eggs as a result of the heightened levels of estrogen
in the water.7 3 Similarly, in Wisconsin scientists discontinued an
experiment after only twenty-four hours when they discovered that
the minnows they were exposing to anti-cholesterol medication, at
levels only slightly above what was present in their normal
environment, were struggling to survive. 74 There is also the certainty
of unforeseen future effects as antibiotic resistance rises and as
research is conducted into the effect of antidepressants on predatory
marine relationships.7 5
F. PPCPRegulation: Why Compliance is Difficult
Attempts to regulate PPCPs are not new. In 1976, the Resource
Conservation and Recovery Act ("RCRA"), enforced by the EPA,
was enacted to regulate the disposal of solid waste and hazardous
waste.76 Under RCRA, hazardous waste is defined as,
a solid waste, or combination of solid wastes, which
because of its quantity, concentration, or physical,
chemical, or infectious characteristics maycause, or significantly contribute to an increase in mortality
or an increase in serious irreversible, or incapacitating
reversible, illness; or pose a substantial present or potential
hazard to human health or the environment when
70. See generally, THEO COLBORN ET AL., OUR STOLEN FUTURE: ARE WE
THREATENING OUR FERTILITY, INTELLIGENCE, AND SURVIVAL?-A SCIENTIFIC
DETECTIVE STORY 172-75 (1997).
71. See id. See also, SCHABECOFF & SCHABECOFF, supra note 4, at 38-67.

72. See Teirney Christenson, Comment, Fish on Morphine: Protecting
Wisconsin's Natural Resources Through A Comprehensive Plan for Proper
Disposal ofPharmaceuticals,2008 Wis. L. REV. 141, 143 (2008).
73. See id Cf Fong, supra note 3, at 143-49.
74. See Christenson,supra note 73, at 144-45.
75. See id. at 143.
76. Resource Conservation and Recovery Act, 42 U.S.C.

(2006).
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improperly treated, stored, transported, or disposed of, or
otherwise managed.7 7
To prevent these wastes from posing a substantial risk to human
health, RCRA is responsible for tracking hazardous waste from the
point of creation to its eventual disposal. As a result, RCRA has
been termed the "cradle to grave" system. 79 To ensure that these
hazardous wastes are safely disposed, RCRA places stringent
requirements on the generators and handlers of hazardous waste postproduction to ensure that transportation, storage, treatment, and,
finally, the disposal of the waste is safely managed.
Currently, RCRA's Subtitle D regulates hazardous waste by
placing solid waste on one of four hazardous waste lists; the F-list,
K-list8 2 , P-list 83 , or U-liSt. 84 Within the last decade, waste products
appearing on RCRA's P-list8 5 and U-list 86 have acquired legal
interest and importance as discussion of the appearance of PPCPs in
solid waste and ground water has become more prevalent.
The P and U-lists contain commercial chemical products that either
have been, or intend to be, discarded by generators. Chemicals on
the P-list are identified as acute hazardous waste 8 and those on the
77. 42 U.S.C. § 6903(5)(a)(b).
78. See RCRA Statute, Regulations & Enforcement, ENVTL. PROT. AGENCY,
http://www.epa.gov/oecaerth/civil/rcra/rcraenfstatreq.html (last updated Mar. 30,
2011).
79. See id. See also Daughton, supra note 5, at 775.
80. See Hazardous Waste Management System, General, 40 C.F.R. §§ 206.1206.43 (2010); RCRA Statute,Regulations & Enforcement, supra note 78.
81. See Lists of Hazardous Waste, 40 C.F.R. § 261.31 (2010).
82. See id. § 261.32.
83. See id. § 261.33.
84. See id.
85. See id. P-listed pharmaceutical wastes include, among others, Warfarin, &
salts, when present at concentrations greater than 0.3% (POOl), Aldrin (P004),
arsenic trioxide (P012), epinephrine (P042), nicotine (P075), Potassium cyanide
(P098), Mercury, (acetato-O)phenyl- (P092), nitroglycerin (P081), physostigmine
salicylate (P 188). Id.
86. See id. U-listed pharmaceutical wastes include, among others, Acetone
(U002), benzene (U019), chloral hydrate (CIV)(U034), chlorambucil (U035),
Methyl chloride (I,T) (U045), Melphalan (U150), mercury (Ul 51), and warfarin, &
salts, when present at concentrations of 0.3% or less (U248). Id.
87. See 42 U.S.C. § 6903(5)(a)(b) (2006); 40 C.F.R. §§ 261.33(e)-(f).
88. See 40 C.F.R. § 261.33(e).
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U-list are identified as toxic waste. 89 There are also characteristic
pharmaceutical waste products not contained in the P or U-lists that
are considered hazardous waste and are nonetheless regulated by
RCRA. 90 Characteristic pharmaceutical waste are those that exhibit
one or more of four characteristics: ignitability,91 reactivity,92
corrosivity,93 or toxicity. 94 There are, however, exceptions to the
characteristic pharmaceutical waste group. If a listed hazardous waste
is listed solely because it exhibits the characteristics of ignitability,
toxicity, corrosivity and/or reactivity, and the waste no longer
exhibits this characteristic, then it is no longer considered hazardous
waste under RCRA.9 5 Additionally, local and state regulations may
be broader or more stringent than RCRA standards. 96 Therefore,
hazardous pharmaceutical waste generators must look to local
regulations when determining the applicable exemptions to ensure
they are interpreting the laws correctly and to maintain compliance
with these standards. 97
There are approximately 600,000 health care facilities in the
United States, 40,000 retail pharmacies, and over 7,000 hospitals.9 8
89. See 40 C.F.R. § 261.33(f).
90. See id. §§ 261.20 - 261.24 (Characteristic hazardous wastes are unlisted
wastes that exhibit one or more of the four characteristics identified by the C.F.R.:
ignitability, reactivity, corrosivity, and toxicity).
91. See id. § 261.21(a)(1).
92. See id § 261.23. The term reactive generally applies to wastes that are
unstable and that undergo violent changes in the presence of water, for example, by
generating toxic vapors or fumes when mixed with water. See id.
93. See id. § 261.22. The term corrosive is generally limited to strong acids and
bases or liquids that are capable of corroding steel above a certain rate per year. See
id.; Amendment to the Universal Waste Rule: Addition of Pharmaceuticals, 73 Fed.
Reg. 73,520, 73,524 (Dec. 2, 2008) (to be codified at 40 C.F.R. pt. 260, 261, 264,
265, 268, 270 and 273) [hereinafter Amendment to the Universal Waste Rule].
94. See 40 C.F.R. § 261.24. Solid waste becomes toxic when the contaminants
listed in 40 C.F.R. § 261.24, such as arsenic (D004), barium (DO05), benzene
(DO18), cadmium (D006) etc. cetera, exceed their permissible regulatory level. Id.
95. See Amendment to the Universal Waste Rule, supra note 93, at 73,524;
Hazardous Waste Identification Rule (HWIR): Revisions to the Mixture and
Derived-From Rules, 66 Fed. Reg. 27,266, 27,283 (May 16, 2001) (to be codified
at 40 C.F.R. pt. 261, and 268).
96. See Amendment to the Universal Waste Rule, supra note 93, at 73,520,
73,524.
97. See id.
98. Amendment to the Universal Waste Rule, supra note 93, at 73,526.'
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In addition, there are more than 300,000 physicians, 99 over 2.9
100
million registered nurses' , and an indefinite number of other
hospital staff and personnel.' 0 These figures do not include dental
offices and veterinary clinics, and their support staff, which may also
be considered hazardous waste generators. 102 With such a large
number of facilities that can potentially be generators of RCRA
hazardous pharmaceutical waste, and therefore subject to generator
regulations, it can be difficult to ensure that regulatory standards are
being met. 103
A facility's generator status, as defined and regulated under RCRA,
depends on the amount of hazardous waste generated at the location
on a monthly basis.104 SQG's and Conditionally Exempt Small
Quantity Generators ("CESQG"s) are subject to fewer requirements
than LQG's.s0 5 For example, SQGs do not need to complete a
biennial report, and have fewer personnel training and contingency
planning requirements than LQGs.106 In addition, CESQGs are not
subject to RCRA's Subtitle C hazardous waste regulations, if they
comply with certain requirements set forth within RCRA.' 0 7

99. Id. at 73,522.
100. The RegisteredNurse Population:Findingsfrom the 2004 National Sample
Survey of Registered Nurses, HEALTH RES. & SERV. ADMIN., U.S. DEPT. OF

http://bhpr.hrsa.gov/healthworkforce/msurvey04/
(last visited April 2, 2011).
101. This could include more or less of the following: hospital administrators,
nurses, physical and occupational therapists, lab techs, nursing assistants, catering
and cleaning services employees, environmental services personnel, pharmacists,
medical students, interns, psychologists, etc.
102. See Definitions, 40 C.F.R. § 260.10 (2010).
103. See id.; see also Standards Applicable to Generators of Hazardous Waste,
40 C.F.R. § 262 (2010).
104. See tbl. 1, infra p. 17.
105. E.g., Special requirements for hazardous waste generated by conditionally
exempt small quantity generators, 40 C.F.R. § 261.5.
106. See 40 C.F.R. § 262.44.
107. See id. § 261.5. CESQGs must comply with requirements set forth in 40
C.F.R. §§ 261.5(f)(3), 261.5(g)(3). Id.
HEALTH AND HUMAN SERVICES,
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The following table displays the differences between LQGs, SQGs
and CESQGs.
Table 1:108
RCRA
Hazardous
Waste
Generator Class

LQG
(large
quantity
generator)

Hazardous
Waste
Accumulation
Limit
per
Month

>/ = 1000 kg

Acutely

> 1 kg

CESOG
(conditionally
small
exempt
quantity
generator)
> 100kg and< </= 100kg
1000kg
SQG
(small
quantity
generator)

</= 1kg

</= lkg

Hazardous
Waste
Accumulation
Limit
per
Month

108. See Definitions, 40 C.F.R. § 260.10; see also 40 C.F.R. §§ 261.5(e)(1), 262.
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However, because the determination of a generator's status, as
large, small or conditionally exempt, is made on a monthly basis, the
status can fluctuate from one month to the next.10 9 If a generator's
status changes, the generator must comply with RCRA requirements
imposed on the new generator class for the quantity of hazardous
waste generated in that month."o
Regulating such a wide array of potentially hazardous waste
material has become problematic for health care professionals.11 '
Hospitals classified as LQGs can typically generate "10,600 tons of
RCRA hazardous pharmaceutical waste annually."ll 2 In contrast,
some retail pharmacies "may only generate [five] pounds of
hazardous pharmaceutical wastes in a year."ll 3
Many facilities have multiple generation points for pharmaceutical
hazardous waste, such as hospital pharmacies, emergency rooms,
operating rooms, and nurses' stations, with several employees
contributing to waste generation.114 For many health care
discarding
the difficulty of appropriately
professionals,
pharmaceutical waste only increases as RCRA hazardous
pharmaceutical wastes are identified by their chemical name, rather
than by commercial name, making it difficult for professionals to
determine whether pharmaceutical waste contains potentially
hazardous or relatively insignificant components.' 15
II. PART II
A. The Need for Regulatory Action
The Universal Waste Rule of 1995 was established to streamline
the collection and management of various hazardous wastes."' This
109. See Amendment to the Universal Waste Rule, supra note 93, at 73,522.
110. See e.g., 40 C.F.R. § 261.5(e)(1); see also ENVTL. PROT. AGENCY, RCRA
ORIENTATION MANUAL 2008: RESOURCE CONSERVATION AND RECOVERY ACT III43 (2008), available at http://www.epa.gov/osw/inforesources/pubs/orientat/.?.
111. See Amendment to the Universal Waste Rule, supra note 93, at 73,526.
112. Id. at 73,522; see also ADDING PHARMACEUTICALS TO THE UNIVERSAL
WASTE RULE, supra note 39, at 7.
113. See Amendment to the Universal Waste Rule, supra note 93, at 73,522.
114. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at ES-61.
115. See 40 C.F.R. § 261.33.
116. See Standards for Universal Waste Management, 40 C.F.R. pt. 273.
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was done in an effort to "greatly facilitate the environmentally-sound
collection and increase the proper recycling or treatment of hazardous
waste."17 Many of the wastes that currently appear on the Universal
Waste List are generated in a variety of settings, and are "managed in
significant volumes in the non-hazardous waste management
system."' Examples include batteries, pesticides, thermostats, lamps
and mercury containing equipment.1 9 Similarly, pharmaceutical
waste products are generated by several types of facilities and are
often managed through a non-hazardous waste management
system. 120
In November 2008, the EPA proposed an amendment of the UWR
to include the addition of pharmaceuticals.121 The proposal stems
from the EPA's recognition that many pharmaceutical hazardous
waste generators have difficultly complying with the requirements of
RCRA subtitle C.1 22 Legislators hope that the addition of
pharmaceutical waste to the UWR will simplify the hazardous waste
management process for generators, further encouraging proper
disposal of pharmaceutical hazardous waste and potentially reducing
the prevalence of these chemical compounds in water. 123 This hope is
reflected in the EPA's stated objective for the amendment to the
UWR proposal which states that the amendment will "simplify
hazardous waste management for the healthcare industry, thereby
encouraging proper disposal of these wastes."l 24
Under RCRA Subtitle C regulations, hazardous waste generators
must comply with requirements regarding the handling, storing,
reporting, transporting, and disposal of hazardous waste.12 5
117. Universal Waste Rule (Hazardous Waste Management System;
Modification of the Hazardous Waste Recycling Regulatory Program), 60 Fed.
Reg. 25,492, 25,492 (May 11, 1995) (to be codified at 40 C.F.R. pt. 9 §§ 260, 261,
262, 264, 265, 266, 268, 270 & 273).
118. Amendment to the Universal Waste Rule, supra note 93, at 73,528.
119. See 40 C.F.R. §§ 273.2 - 273.5.
120. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra
note 39, at ES-1. See also discussion, supra Part I, D (discussing the types of
facilities that generate pharmaceutical waste and their various disposal methods).
121. Amendment to the Universal Waste Rule, supra note 93, at 73,520.
122. See id at 73,522.
123. See id.
124. ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note
39, at ES-1.
125. See id
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However, many pharmaceutical waste generators are either unaware
of these regulations, or if they are aware of the regulations, the
hazardous waste generator may have difficulty training personnel in
the proper waste management.' 26
Several factors can contribute to a generator's inability to secure
employee compliance with RCRA Subtitle C standards. First, many
healthcare workers generally receive no training on hazardous waste
management and are thus unfamiliar with federal standards.127 in
addition, safety and environmental management personnel are
sometimes not aware of the "active ingredients and formulations of
pharmaceutical" hazardous waste "and cannot make the hazardous
waste determination for all the waste generated in patient rooms" or
nurses' stations.128 Compounding the issue is the difficulty involved
with establishing separate collection systems for non-hazardous
pharmaceutical waste and hazardous pharmaceutical waste,
especially as this waste can stem from multiple sources within a
given facility.129 The plethora of pharmaceutical waste and the
differentiation between hazardous and non-hazardous waste groups
have rendered many facilities non-compliant with RCRA hazardous
waste regulations or have rendered them incapable of properly
managing their waste streams.' 3 0
B. Defining the Issue

Under the proposed amendment, a pharmaceutical is defined as:
. . any chemical product, vaccine or allergenic (including
any product with the primary purpose to dispense or deliver
a chemical product, vaccine or allergenic), not containing a
radioactive component, that is intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of
disease or injury in man or other animals; or any chemical
126. See id.; see also Amendment to the Universal Waste Rule, supra note 93, at
73,526; Oliver & Chapman, supra note 41, at ES-1.
127. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra
note 39, at ES-1. See also Amendment to the Universal Waste Rule, supra note 93,
at 73,526.
128. ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note

39, at ES-1.
129. See id.
130. See id.
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product, vaccine or allergenic (including any product with
the primary purpose to dispense or deliver a chemical
product, vaccine or allergenic), not containing a radioactive
component, that is intended to affect the structure or
function of the body in man or other animals.13 1
Several over-the-counter pharmaceuticals and commonly used
medical supplies are included in this definition.132
However, not included in the proposed definition are "sharps,"l 33
"infectious or biohazardous 'red-bag' waste," 34 "waste chemicals
from laboratories, medical devices,"'l 3 5 "dental amalgams, personal
hazardous
with
contaminated
equipment
protective
hazardous
up
pharmaceuticals,"l36 cor any material used to clean
131. Amendment to the Universal Waste Rule, supra note 93, at 73,522. "This
definition includes products, such as transdermal patches, and oral delivery devices,
such as gums or lozenges." Id. at 73,523. This definition does not include "sharps
or other infectious or biohazardous waste, medical devices, not used for delivery or
dispensing purposes, equipment, contaminated personal protective equipment"
(scrubs, gowns, gloves, etc.) "or contaminated cleaning materials." Id. The
amendment adapted its definition of "pharmaceutical" from the Federal Food, Drug
and Cosmetic Act's definition of "drug." Id. See also 21 U.S.C. § 321(g)(1)(B)
(2006).
132. See Amendment to the Universal Waste Rule, supra note 93, at 73,522.
"[P]ills or tablets, medicinal gums and lozenges, medicinal liquids, ointments and
lotions, intravenous (IV) or other compounded solutions, chemotherapy drugs,
vaccines, allergenics, medicinal shampoos, antiseptics and medicinal dermal
patches, and delivery devices with the primary purpose to deliver or dispense a
chemical product, vaccine or allergenic." Id. at 73,523.
133. Amendment to the Universal Waste Rule, supra note 93, at 73,523. Sharps,
"needles or syringes with needles," and are not included under the proposed
amendment because they are considered "medical wastes", which are currently
regulated by states and localities. Id.
134. Id. at nn. 4-5. "Infectious or biohazardous "'red-bag"' wastes[,]" like sharps,
are also not included under the proposed amendment as they are regulated by states
and localities. Id.
135. Id. at n.6. Medical devices such as "blood pressure cuffs, mercury
thermometers, and x-ray films" are not regulated under the proposed amendment
because they do not fall within the definition of a "pharmaceutical" as defined by
the proposal. Id. However, these products may have agents that display hazardous
waste characteristics, for example mercury (D009), and thus still may be subject to
RCRA requirements. Id. See also 40 C.F.R. § 261.24 (2010).
136. Amendment to the Universal Waste Rule, supra note 93, at 73,523.
Contaminated "personal protective equipment" and "clean-up materials" are not
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pharmaceutical waste" spills.'3 7 Additionally, under the proposed
amendment, "residues" that result from the "manufacture, production,
or distribution of .. . pharmaceuticals," are not deemed to be
pharmaceutical wastes and, therefore, will not be regulated under the

proposed amendment.138
C. Summary of the Proposal

As the proposal stands, hazardous pharmaceutical waste generators
may choose to continue management under RCRA Subtitle C
guidelines or they may choose to manage their waste under the
UWA.1 39 The key differences between the two requirements include
the following:
1. Accumulation Time Limits and Generation Thresholds
Under RCRA regulations, LGQs may store hazardous waste onsite
for up to ninety days, while SGQs may store hazardous waste onsite
for 180 to 270 days.14 0 Under the UWA, hazardous pharmaceutical
waste may be stored onsite for up to one year.141 Generation
thresholds 42 will be eliminated and "accumulation limits" will be
bifurcated into two broad categories that allow for greater
accumulation amounts. 143 As CESQGs will be eliminated, SQGs will
included in the proposed amendment because they may be "different in form and
composition from the universal waste they come from." Id. at n.7.
137. Id. at 73,523.
138. Id. The EPA has chosen not to regulate wastes generated in the "industrial
setting" because are not well suited for regulation under the universal waste
management system. See id.; Universal Waste Rule (Hazardous Waste
Management System; Modification of the Hazardous Waste Recycling Regulatory
Program), 60 Fed. Reg. at 25,514.
139. See Amendment to the Universal Waste Rule, supra note 93, at 73,520.
140. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra
note 39, at ES-2.
141. See id. at ES-1.
142. Id. Generators of RCRA hazardous wastes are identified as CESQG, SQG,
or LQG based on the amount of waste generated (generation threshold) in a certain
amount of time (accumulation time limit). Id. Generation thresholds and
accumulation time limits will also determine whether a generator must comply with
additional requirements under RCRA. Id.
143. See Amendment to the Universal Waste Rule, supra note 93, at 73,535,
73,536 (Generators will now have the option to accumulate waste for one year or
more than one year).
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simply be required to stay within an accumulation limit of 5,000kg
per year and LGQs will be permitted to accumulate anything above
5,000kg per year; 144 therefore, generators will no longer be concerned
with an episodically changing generator status, as acutely hazardous
waste accumulation amounts increase and decrease from month to
month.
2. Inspecting Waste in Storage
Under RCRA Subtitle C, SQGs and LQGs must conduct weekly
inspections of any hazardous waste kept in storage.14 5 Under the
Universal Waste Rule, universal waste handlers are not required to
conduct regular inspections of their stored universal waste. 146
Interestingly, the proposed amendment does not discuss inspection
requirements and generators are left in the dark as to whether these
inspections will be required if they opt to comply with the proposed

amendment. 147
3. Transportation of Waste and the Preparation of a Manifest
RCRA allows the transportation of hazardous waste by registered
hazardous waste transporters only.148 In contrast, the Universal Waste
Rule allows waste to be transported by common carriers, meaning a
generator may chose to transport its own universal waste;149 the
proposed amendment will allow generators to dispose of
pharmaceutical waste generated at their facility themselves. In
addition, unlike subtitle C requirements for LQGs and SQGs, the
Universal Waste Rule does not require the preparation of a
manifest 5 0 for the shipment of waste offsite, unless the waste is
transported through a state that does not recognize the waste as
144. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at ES-2.
145. See id. at ES-5.
146. See id. at ES-2.
147. See Amendment to the Universal Waste Rule, supra note 93, at 73,520.
148. See. ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at ES-5.
149. See id.

150. See 40 C.F.R. § 262.20(a)(1) (2010) ("A generator who transports, or offers
for transport a hazardous waste for offsite treatment, storage, or disposal, or a
treatment, storage, and disposal facility who offers for transport a rejected
hazardous waste load, must prepare a Manifest. . . .") Id.
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universal waste.1 5 1 If pharmaceutical waste products are included in
the universal waste stream, the manifest requirement will also be

eliminated.152
4. Emergency Preparedness
Under RCRA Subtitle C, generators must develop contingency
plans for accidental spills of hazardous waste and procedures to
appoint an emergency coordinator for the facility. 153 The UWA will
still include emergency preparedness standards and employee
training requirements, though they will differ from those of RCRA.15 4
III. PART III

A. Necessary Changes to FederalRegulatory Standards
Several factors make compliance with federal hazardous waste
standards difficult. The foremost difficulty is the issue of defining
"hazardous" waste. Several federal statutes regulate hazardous
pharmaceutical waste disposal. 5 5 Additionally, an agency's
jurisdiction over hazardous waste depends on factors such as the
waste's source, method of disposal, or end user. 156 Even when a
generator attempts to properly comply with RCRA, the chemical
ingredients that appear on the P-list and U-list can be found in at least
100 pharmaceutical products, significantly hindering the
identification process for the generator's employees, as many are
unaware of the appearance of these chemical ingredients in each
drug.'5 7 Also, a number of drugs and pharmaceuticals meet RCRA's
151. See Amendment to the Universal Waste Rule, supra note 93, at 73, 543-44.

152. See ADDING
note 39, at ES-5.

PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE,

supra

153. See id

154. See id at 4-5.
155. See Amendment to the Universal Waste Rule, supra note 93, at 73,527.
156. See infra pp. 25-31.
157. See Amendment to the Universal Waste Rule, supra note 93, at 73,526. Of
the wastes included on RCRA's P and U-lists, roughly thirty-one contain chemical
ingredients used in pharmaceutical drugs. When this information is extrapolated,
one can estimate that these thirty-one chemical ingredients may result in the
appearance of RCRA hazardous waste in 100 or more pharmaceuticals. For
example, "warfarin and salts (POOl) are used in at least [six] commercial
pharmaceutical products, and Melphalan (Ul50) is used in [five] products." Id.
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definition of characteristic hazardous wastes and are therefore not
listed on the P-list or U-list.
The issues that make compliance
difficult, as well as other miscellaneous problems not solved by
current regulation, are discussed in this section.
1. Difficulties with Compliance
a. Determining Whether a PharmaceuticalWaste is Subject to
Hazardous Waste Regulations

Solid waste generators are required to determine whether their
solid waste is "hazardous waste" under RCRA.1 59 If waste is not
properly classified at the commencement of the generator's
compliance procedure, the objective of the "cradle to grave" system
is undermined. The following are the steps a solid waste generator
must take to determine whether it is generating RCRA hazardous
waste:
Step 1: Is the substance a solid waste as defined in 40
C.F.R. 261.2?l60
Step 2: Is the substance excluded from the definition of a
solid waste under 40 C.F.R. 261.4?l61
Step 3: Is the substance a hazardous waste listed in Part
261.30-261.35?162

Step 4: If not, does the substance exhibit any of the
characteristics defined in Part 261.20 - 261.24?163
The process is tedious, potentially confusing, time consuming, and
impractical. To make matters worse, at the conclusion of this process,
generators may be forced to determine whether their waste is

Pharmaceuticals may also contain chemicals that appear on the toxicity list, "such
as arsenic or chromium." Id. at n. 26.
158. See Id. at 73,524.
159. See 40 C.F.R. § 262.11 (2010).
160. See id.
161. See id.

162. See id.
163. See id; see also Amendment to the Universal Waste Rule, supra note 93, at
73,523, 73,527.
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hazardous under other federal and/or state regulations and then
comply with those corresponding regulatory measures.1 64
The difficulty involved with this process is reflected in an EPA
Assessment conducted before the introduction of the amendment.' 65
According to the Assessment, "there are over 7,000 hospitals, and
approximately 72,000 long-term-care facilities, 27,000 veterinary
care facilities, 40,000 retail pharmacies, and several hundred
thousand offices of doctors, dentists and other health care service
providers in the United States."l 66 All of these entities are potential
pharmaceutical waste generators and many generate wastes that are
deemed hazardous under RCRA.
However, of these figures, only
ninety-four hospitals and nineteen pharmacies identified themselves
as LQGs of hazardous waste. 1 For hospitals, this is a little over ten
percent, and for pharmacies a small fraction of a percent.1 6 Even if
the vast majority of pharmaceutical waste generators classify
themselves as SQGs or CESQGs, this still reflects the fact that large
and small facilities know very little about RCRA and its regulatory
requirements. 170
The FDA approves thousands of pharmaceutical drugs for use.
Each year a generator disposes of hundreds, or even hundreds of
thousands, of different types of pharmaceutical waste.1 7 2 Attempting
to determine RCRA regulated hazardous pharmaceutical waste, Drug
164. See discussion supra notes 132-33. Mixed waste, for example, can contain
both RCRA hazardous characteristics or special nuclear, or byproduct material,
making it subject to Atomic Energy Act of 1954 (AEA) requirements. See
Amendment to the Universal Waste Rule, supra note 93, at 73,523, 73,532; See
also Radioactive Waste; Byproduct Material, 52 Fed. Reg. 539 (May 1, 1987).
165. See generally ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE
RULE, supra note 39.
166. Amendment to the Universal Waste Rule, supra note 93, at 73,526; ADDING
PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note 39, at 8.
167. See Amendment to the Universal Waste Rule, supra note 93, at 73,526;
ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note 39, at 8.
168. Amendment to the Universal Waste Rule, supra note 93, at 73,526.
169. ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note
39, at 8.
170. See Amendment to the Universal Waste Rule, supra note 93, at 73,526.
171. See Drugs@FDA: FDA Approved Drug Products, FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (last visited Mar.
29, 2011) (Each drug is indexed by name. Click on the name of the drug to receive
FDA labeling information).
172. See discussion supraPart I, D.
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Enforcement Agency ("DEA") regulated waste,1 7 3 Atomic Energy
Act ("AEA") regulated wastes' 74 or the Health Insurance Portability
and Accountability Act ("HIPAA") regulated waste' 7 5 and separating
them from potentially non-hazardous pharmaceutical waste, at
multiple points of origin within facilities (such as nursing stations,
emergency rooms, intensive care units, operating rooms et cetera),
can be difficult and realistically impossible.
Furthermore, under the proposed amendment, the daily collection
of small volumes of hazardous waste, from multiple source points
within a facility, will accumulate in waste storage bins for up to a
year (whether the bins will be covered or uncovered is still up for
debate).1 76 Will the determination of the correct waste stream as
hazardous or non-hazardous be made before the pharmaceuticals
enter storage bins or after? Will facilities be able to accurately wade
through a year's worth of pharmaceutical waste and separate waste
streams efficiently? Even more troubling is the question of whether
all pharmaceutical waste will be considered "non-hazardous" for the
The implications for
purpose of easing generator's burdens.
pharmaceuticals regulated under the Controlled Substances Act
("CSA") will be impacted as facilities must effectively regulate waste
shortages and prevent employees from misappropriating addictive
drug substances. These are difficult questions and the proposed
amendment seems content to ignore them in favor of easing the
financial burden on generators.' 7 7
The UWA allows generators to choose between continued
regulation under RCRA Subtitle C or regulation under the UWA.17 8
Under the UWA, the hazardous waste identification process will be
simplified most notably by the removal of RCRA distinction between
P-listed wastes and other hazardous wastes to ease the accumulation

173. See Amendment to the Universal Waste Rule, supra note 93, at 73,527;
supra note 39, at
n.8.
174. See Amendment to the Universal Waste Rule, supra note 93, at 73,527.
175. See id.
176. Id. at 73,535-36.
177. Id. at 73,527, 73,528, 73,531.
178. See id. at 73,520.
ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE,
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and volume generation limits on generators.1 79 The framers of the
amendment hoped to streamline the disposal process and allow
generators to place non-hazardous pharmaceutical waste in the same
or in similar, waste management streams as RCRA hazardous
pharmaceutical waste.' 8 0 The issues of identification and sorting
would be considerably reduced if not completely nullified, as
generators could simply dump all pharmaceutical drugs in one
universal waste bin.
While this proposal makes compliance with federal standards
easier for generators, it impairs the "cradle to grave" system, one of
the more noble aspects of RCRA. The streamlining of waste
combined with relaxed recordkeeping and recording requirements
will leave the EPA without valuable information about disposal rates
and may tempt generators to relax disposal standards.' 82 The EPA
should still require that hospitals inspect hazardous waste containers
over the course of the year and ensure that containers remain closed
when not in use. Manifests should be required for off-site shipment of
hazardous waste when the amount of waste shipped exceeds a certain
quantity, and the waste should be in the hands of registered hazardous

waste disposers.1 83
While the UWA's relaxed standards encourage generators to
dispose of all pharmaceutical waste in the same stream,184 thereby
easing the hazardous waste identification process, issues of
179. See id. at 73,530. This is also a positive addition because generators no
longer have to worry about a change in generator status due to the accumulation of
acute hazardous waste. See discussion supra Part II, C.
180. See Amendment to the Universal Waste Rule, supra note 93, at 73,527;
ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note 39, at 1.
181. See discussion supra Part II, C.
182.

See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at ES-2-4. Under the proposed rule, SQGs have no recordkeeping
requirements, hazardous manifests are not required for off-site shipment for either
SQGs or LGQs, generators are no longer required to ship hazardous pharmaceutical
wastes to registered hazardous waste disposers, there are no notification
requirements for SQGs, there are no container inspection requirements and there is
no requirement that containers remain sealed during storage. See id.
183. ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra note

39, at ES-3. As the UWA will encourage generators to ship larger quantities of
potentially hazardous waste, the EPA should stay abreast of these shipments. The
EPA could seek comment from generators as to what quantity would be a
reasonable to trigger manifest requirements.
184. See Amendment to the Universal Waste Rule, supranote 93, at 73,530.
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identification will inevitably arise. The UWA does not supersede or
amend other federal regulations and will only affect the states that
choose to codify the amendment.
For instance, if radioactively
contaminated wastel 86 is inadvertently dumped in a UWA-regulated
pharmaceutical waste bin, the waste will still become mixed, lowlevel hazardous waste ("LLW") and will then be subject to regulation
Similarly, if generators are no longer forced to
under the AEA.
differentiate between hazardous and non-hazardous pharmaceutical
waste, drums will be filled with a m6lange of pharmaceutical waste
substances, any of which may individually, or when combined,
exhibit RCRA hazardous waste characteristics outlined under 40
C.F.R. § 261.21 - § 261.24. At some point it will become inevitable
for a generator to make a determination as to the status of a
pharmaceutical waste, whether it be that the drug, or combination of
drugs, is "hazardous," a controlled substance, or a mixed waste.1
Eliminating the issue of differentiating between wastes on the P or Ulist does not eliminate the issue of identification.
Instead of trying to eliminate the identification issue altogether, the
EPA should consider developing a list that identifies all
pharmaceuticals by both their commercial and chemical names in an
easily accessible format. 189 Access to this list would simplify the
identification process for generators who choose to continue
185. See id. at 73,520.
186. See ENVTL. PROT. AGENCY, GUIDANCE ON THE DEFINITION AND
IDENTIFICATION OF COMMERCIAL MIXED Low-LEVEL RADIOACTIVE AND
http://www.epa.gov/radiation/mixed-waste/guidanceWASTE,
HAZARDOUS

identification-llmw.html.
187. See id.; see also Amendment to the Universal Waste Rule, supra note 93.
188. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra
note 39, at ES-3. UWA will no longer require a mandatory waste handling training
program for employees of LGQs. Id. With the addition of a new regulatory scheme
individuals may still experience issues correctly identifying hazardous wastes and
determining the proper method of disposal. Id.
189. Charlotte Smith and James McCauley have patented a pharmaceutical
hazardous waste identification and management system. See Pharmaceutical
Hazardous Waste Identification and Management System, U.S. Patent No.
7,096,161, figs. 6 & 7 (filed Dec. 12, 2002) (issued Aug. 22, 2006). The system can
be used by generators to provide personnel with the information necessary to
determine which pharmaceuticals are hazardous wastes as defined by state,
national, and international regulations. Id. This program is particularly impressive
as it also provides information on hazardous pharmaceuticals as defined by
Occupational Safety and Health Administration ("OSHA") regulations. Id.
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operating under RCRA.190 The EPA should also encourage
manufacturers to actively participate in the disposal and recycling
process.191 Drugs that still have economic value to the generator,
because they are being returned to a reverse distributor' 92 for
example, are not considered hazardous waste and therefore are not
subject to RCRA.193 Perhaps if manufacturers (and reverse
distributors) were encouraged to collect drugs that are damaged, no
longer packaged, or impaired in some way, these drugs could be
recycled or disposed of efficiently.194
b. Overlap in Regulation
Pharmaceuticals are subject to various other regulations
administered by other federal agenciesl 95 and their regulatory
regimes, as well as by state and local regulations. 196 The overlap in
regulatory requirements can make the management of pharmaceutical
waste a complex endeavor for generators as federal statutes use the

190. See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE RULE, supra

note 39, at ES-1; see also Amendment to the Universal Waste Rule, supra note 93,
at 73,523.
191. See Stephen Musson & Timothy Townsend, Management of Discarded
Pharmaceuticals, 3 PRAC. PERIODICAL OF HAZARDOUS, TOXIC, & RADIOACTIVE

WASTE MGMT. 89 (1998). Manufacturers currently accept pharmaceuticals and in
some instances provide rebates for the drugs when returned. Id. at 91. The EPA
should support the return of pharmaceuticals to the manufacturer, as this will
encourage recycling alternatives and charitable donations. Id.
192. Reverse distributors are companies that recycle or dispose of controlled
substances. See 21 C.F.R. §§ 1300.01(b)(41), 1307.1l(a)(2) (2010).
193. See Amendment to the Universal Waste Rule, supra note 93, at 73,532.
194. Cf id. at 73,533 (under the proposed amendment, reverse distributors may
become handlers of pharmaceutical waste enabling them to receive both universal
pharmaceutical waste and unused waste). While reverse distributors may not
receive pharmaceutical waste directly from consumers because of Drug
Enforcement Agency (DEA) restrictions, pharmaceutical take-back programs may
choose to ship the wastes received from households and consumers to these reverse
distributors for disposal. Id. If this is the case, why not allow reverse distributors to
receive drugs from the general public directly?
195. See id. at 73,537. For example, pharmaceuticals can be subject to the CSA
and DEA regulations; Health Insurance Portability and Accountability Act
("HIPAA") patient privacy requirements; and the AEA. See id.
196. See id. Some states and localities may regulate "infectious pharmaceutical
wastes" as hazardous, infectious, or both. Id.
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same language to define very different concepts within the purview
of each individual piece of legislation and vice versa.197
For example, the Federal Food, Drug, and Cosmetic Act
("FFDCA") and the CSA both regulate certain aspects of
pharmaceuticals with their own respective definitions.198 So too does
the DEA, which often regulates the disposal of pharmaceutical
drugs.199 For example, what the FFDCA considers a "device," the
proposed amendment considers a "container." 2 00 How the FFDCA
defines a "drug," is how the amendment defines a
"pharmaceutical." 20 1 Thus, in order to determine whether a particular
waste is managed under the AEA, or FFDCA, or RCRA, or even the
DEA, the generator must first look to the definitions housed in each
regulation, as the definitions contained in other regulatory programs
may differ.2 02
The UWA only adds to the plethora of other federal
pharmaceutical regulations. 203 As generators still have the option to
continue regulation under RCRA,2 0 4 the UWA only forces generators
to consider whether they dare venture deeper into this regulatory
labyrinth.2 0 5 The intentions of the EPA, as expressed within the
proposal, indicate that the UWA will simply encourage generators to
employ other methods of disposal, such as using a reverse
207
distributor2206 or a pharmaceutical take-back program.
However,
197. See id.
198. See id. at 73,523.
199. See discussion supra Part I, D (discussing the flushing methods used by
coroners offices in order to comply with DEA regulations).
200. Amendment to the Universal Waste Rule, supranote 93, at 73,523.
201. Id.
202. Id.
203. See supra note 196 and accompanying text.
204. Amendment to the Universal Waste Rule, supranote 93, at 73,520.
205. See supra Part II, C.
206. See Definition and Registration of Reverse Distributors, 68 Fed. Reg. at
41222, 41228 (July, 11 2003) (to be codified at C.F.R. pts. 1300, 1301, 1304, 1305,
and 1307). Reverse distributors are defined as "a registrant who receives controlled
substances acquired from another DEA registrant for the purpose of (i) returning
unwanted, unusable, or outdated controlled substances to the manufacturer or the
manufacturer's agent; or (ii) [w]here necessary, processing such substances or
arranging for processing such substances for disposal." Id. "When reverse
distributors return unwanted, unusable, or outdated controlled substances acquired
from legitimate medical, scientific, research or other industrial channels to a
manufacturer or a manufacturer's agent, they must follow the same DEA
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reverse distribution is governed by the DEA and does not apply to all
hazardous pharmaceutical waste,20 8 therefore, a generator that uses
reverse distribution will have to comply with DEA requirements in
addition to other pharmaceutical waste requirements.
c. Accumulation Time Limits and Generation Thresholds
Many health care facilities, and other pharmaceutical waste
generators, have expressed concern with the monthly accumulation
time limits set for hazardous waste generators. 209 Pharmaceutical
waste typically accumulates in small volumes over a long period of
time.210 As a result, generators that choose to outsource their
hazardous waste disposal to off-site sources are burdened by
generation thresholds that prevent them from accumulating more P or
U-listed waste than legally permissible for their generator status. For
many facilities, the conflict between generation thresholds and
accumulation time limits can make the cost of off-site shipment
211
inefficient.
Many hospitals and health care facilities have episodically shifting
RCRA hazardous waste generator status, due to their generation of P212
Hazardous container requirements can
listed pharmaceutical waste.
also contribute to a change in a generator's status.21 3 If facilities do
not clean containers holding P-listed wastes, the weight of the
container alone, not the chemical residue within the container, can

requirements as distributors follow." Id. See also Disposal of Controlled
Substances, 21 C.F.R. § 1307.21(b)(4) (2009).
207. See infra Part III, B.
208. See supra text accompanying note 195 and accompanying text.
209. Amendment to the Universal Waste Rule, supra note 93, at 73,522, 73,527.
210. See id. at 73,527.
211. See id.
212. See id. P-listed wastes, or acutely hazardous wastes, have a low generation
threshold. If a CESQGs generates more than onel kilogram (kg) a month they
exceed their threshold and become a LQG. Id.
213. See Identification and Listing of Hazardous Waste, 40 C.F.R. § 261.33(c)
(2009) (requiring containers once holding P-listed hazardous wastes be considered
P-listed hazardous wastes, unless considered "RCRA empty"). See also 40 C.F.R. §
261.7(b)(13)(iii)(B)(3)(i) (Containers are considered RCRA empty once they are
triple-rinsed with an appropriate solvent. The solvents and liquid components used
during the triple-rinsing of containers are also RCRA hazardous wastes because of
the "mixture and derived-from rule"). 40 C.F.R. § 261.3(a)(2)(iv).
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push the facility from CESQG status into LQG status leaving the
facility subject to more rigorous requirements. 2 14
Requirements that fluctuate monthly only add to the difficulty of
managing pharmaceutical waste appropriately under RCRA
hazardous waste regulations. Additionally, given the relatively small
number of low volume pharmaceutical wastes generated daily, 215 the
benefit of the additional P-list requirements can be burdensome.
To combat this issue, the UWA proposes different accumulation
time limits for LQGs and SQGs alike. 2 16 The increase in limits will
address the issue of fluctuating generator statuses and, if
implemented, will be a positive amendment to RCRA standards.
However, the inclusion of accumulation limits carries with it the
implicit assumption that universal wastes are collected and stored in a
marked container separate from other hazardous wastes that may be
subject to other state and federal regulations; 2 17 therefore, the issue of
waste determination and overlap in regulation will still exist.
Without fully addressing issues of waste determination and overlap in
regulation, an increase in storage accumulation time limits and
quantities will simply encourage generators not to make accurate
hazardous waste determinations and may result in inadvertent noncompliance by waste generating facilities.
B. ProposedSolutions

Many of the issues discussed above only scratch the surface of the
difficulties associated with pharmaceutical waste management.
While the proposed amendment to the Universal Waste Rule is
laudable, as it will address many of the issues broached in the
previous section, there are still many issues that abound in regard to
pharmaceutical waste disposal in the United States. This section
discusses some of the proposals posed by scientists in the federal
regime and will look to the role consumers play in the disposal

214. See Amendment to the Universal Waste Rule, supra note 93, at 73,527.

215. See id. at 73,532.
216. See id. at 73,536.
217. Under the proposed amendment, all containers holding UWA waste must be
marked with the words "Universal Waste - Pharmaceuticals" or "Waste
Pharmaceuticals." See ADDING PHARMACEUTICALS TO THE UNIVERSAL WASTE
RULE, supra note 39, at ES-2; Amendment to the Universal Waste Rule, supra note
93, at 73,536.
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process.218 These proposals could reduce the concentration of
pharmaceuticals in wastewater, make proper disposal of
pharmaceuticals more viable and convenient, and potentially result in
actual compliance with current regulations.
1. Expanded Use of Reverse Distribution and Pharmaceutical TakeBack Programs
Many generators currently use reverse distribution to dispose of or
return unused or expired pharmaceuticals. 2 19 This activity could be
expanded, creating a more comprehensive reverse distribution model
inclusive of consumer pharmaceuticals. 220 If reverse distributors
keep collection records, the information could be used to better
understand the needs of consumers. Many drugs are returned unused
each year, costing the pharmaceutical industry billions of dollars

218. See generally Christian G. Daughton & Thomas A. Ternes,
Pharmaceuticalsand PersonalCare Products in the Environment:Agents ofSubtle
Change?, 107 ENVT'L. HEALTH PERSP. 907 (Supp. 6 1999); Christian G. Daughton
& Tammy L. Jones-Lepp, Pharmaceuticalsand PersonalCareProducts in the
Environment: Scientific and Regulatory Issues, in Pharmaceuticals and Care
Products in the Environment (2001); Susan T. Glassmeyer et al., Disposal
Practicesfor UnwantedResidential Medications in the United States, 35(3) ENV'T.
INT'L. 566 (2009) (Daughton is the PPCP pioneer and has spent has spent over a
decade publishing articles in books and publications dedicated to the subject. His
proposals and suggestions for the management of PPCPs significantly influenced
the regulation of PPCPs today. For an exhaustive list of Daughton's publications
please look to his biography on the EPA website available at http://www.epa.gov/
esd/bios/daughton.htm). The UWA will not address disposal methods used by
consumers. See Amendment to the Universal Waste Rule, supra note 93, at 73,532.
However, consumers also contribute to the disposal of these wastes.
Pharmaceutical sales reached $286.5 billion in the United States last year. See Press
Release, IMS Health Inc., Lance Longwell, IMS Health Reports U.S. Prescription
Sales Grew 3.8 Percent in 2007, to $286.5 Billion, IMS HEALTH INC. (Mar. 12,
2008), availableat http://www.imshealth.com/portal/site/imshealth/menuitem
(follow "Press Room" hyperlink; then follow "Press Releases" hyperlink; then
follow "2008" drop down to "IMS Health Reports U.S. Prescription Sales Grew
3.8 Percent in 2007, to $286.5 Billion" hyperlink).
219. See supra note 195.
220. See Daughton, supra note 5, at 776; see also supra note 195 and
accompanying text.
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annually and unnecessarily contributing to pharmaceutical waste
streams.2 2 1
In addition, many PPCPs with RCRA hazardous characteristics are
defacto exempt from federal standards because the laws do not apply
to consumers.222 Many pharmaceutical take-back programs, accepting
the free return of prescription medications, exist across the
country.223 Pharmaceutical take-back programs ensure that the
consumer's medication is disposed of in compliance with state and
federal regulations.224
However, expanded use of reverse distributors and pharmaceutical
take-back programs will only be effective if federal regulations adopt
practices.
disposal
pharmaceutical
sound
environmentally
Permissible flushing and the discretionary disposal of
pharmaceuticals cannot be the solution to proper waste
management.2 2 5

221. Physicians sometimes receive free pharmaceutical samples from the
manufacturer. These samples may also contribute to the number of returned unused
pharmaceuticals each year. See Daughton,supra note 5, at 776.
222. See 40 C.F.R. § 261.4(b)(1) (2009). For instance, household hazardous
wastes are excluded from RCRA and are not subject to its regulations. Id. See also
Amendment to the Universal Waste Rule, supra note 93, at 73,522, 73,525, 73,526,
73,532, 73,533.
223. The Drug Take Back Network, Local Efforts, TAKEBACKNETWORK.COM,
http://www.takebacknetwork.com/localefforts.html (last visited April 11, 2011)
(providing links to a list of states with information on permanent and regularly
recurring take-back events).
224. Amendment to the Universal Waste Rule, supra note 93, at 73,526.
225. See Disposal of Controlled Substances, 21 C.F.R. § 1307.21(b)(4) (2009)
("The Special Agent in Charge shall authorize and instruct the applicant to dispose
of the controlled substance . .. (4) By such other means as the Special Agent in
Charge may determine to assure that the substance does not become available to
unauthorized persons.") In October 2009, the Office of National Drug Control
Policy changed their pharmaceutical waste disposal statement to no longer reflect
the promotion of drug flushing (unless required to do so by FDA label). Proper
DisposalofPrescriptionDrugs, OFF. OF NAT'L DRUG CONTROL POL'Y, (October
2009), availableat http://www.whitehousedrugpolicy.gov/publications/pdf/
prescripdisposal.pdf. In the guidelines,the FDA suggests that consumers mix
unwanted drugs with "cat litter or used coffee grounds" before sealing the drugs in
a plastic bag or container and throwing them away. Id. Ironically, hazardous
household waste is regulated by states and should be treated differently than nonhazardous household waste. See ENVTL. PROT. AGENCY, HOUSEHOLD HAZARDOUS
WASTE, http://www.epa.gov/ epawaste/conserve/materials/hhw.htm (last visited
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2. No More Flushing
Flushing remains a permissible means of disposal under RCRA and
the CSA. 226 The FDA also endorses flushing certain drugs.227 If
facilities choose to operate under the UWA, use reverse distribution
or pharmaceutical take-back programs as viable methods of disposal,
or even if they choose to continue to comply with RCRA hazardous
waste requirements, pharmaceuticals can still enter the environment
through permissible flushing.
Flushing medication or disposing of medications down the drain is
unconscionable in the face of developing research.22 8 The EPA, FDA
and DEA need to synthesize their approach and amend the conflicts
present in the current regulatory system. These agencies need to
implement a national standard for the proper disposal of
pharmaceutical waste to promote the incineration of damaged or
adulterated medication. 229 Medications that remain unused should be
returned to the manufacturer for recycling.2 30 This should be a
blanket policy that is applicable to both to consumers and generators.
Consumers and generators who do not have access to RCRA certified
April 11, 2011). States and localities may or may not provide for year round
collection and proper disposal of these wastes. See id.
226. RCRA has a domestic sewage exception that allows for the disposal of
"Any mixture of domestic sewage and other wastes that passes through a sewer
system to a publicly-owned treatment works for treatment." 40 C.F.R. §
261.4(a)(1)(ii) (2009). See Disposal of Controlled Substances, 21 C.F.R. §
1307.21(b)(4)(2009). But cf H.R. 1191, 11Ith Cong. (2009).
227. The FDA suggests, and sometimes requires, that certain drugs be flushed.
Examples include, but are not limited to, Actiq (fentanyl citrate), Daytrana
transdermal patch (methylphenidate), Duragesic transdermal system (fentanyl),
Tequin tablets (gatifloxacin), and Fentora (fentanyl buccal tablet). Index to DrugSpecific Information, supra note 55. But cf H.R. 1191.
228. See discussion supra Part I, E. See also Kolpin et al., supra note 6, at 1210
(discussing evidence that select chemical combinations can exhibit additive or
synergistic toxic effects and OWCs that "exhibit weak hormonal activity with the
potential to disrupt normal endocrine function"). See also H.R. 1191.
229. See. H.R. 1191. See also Incinerators, 40 C.F.R. §§ 264.340 - 264.351
(2009). The problem of pharmaceutical waste disposal is massive, and there are
currently no viable methods that will result in the true "disposal" of these
substances. See Despo Fatta-Kassinos et al., supra note 37, at 271-72. Even those
pharmaceuticals that have been disposed of will have a continued presence in water
and soil for decades and perhaps even centuries to come. See id. at 264-69, 272.
230. The EPA should encourage pharmaceutical manufacturers to play a more
active role in the recycling of the pharmaceuticals they dispense.
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incinerators could then employ the services of pharmaceutical takeback programs and reverse distributors to handle proper disposal. To
further aid consumers, pharmacies can also serve as free drop-off
points where unused and unwanted pharmaceuticals may be returned
for recycling or proper disposal.2 3 '
3. Drinking Water Standards
Many pharmaceuticals enter SWTs and end up in the drinking
water supplies of residents. 232 Although more research must be
conducted on the effects of pharmaceutical disposal on human and
aquatic life, if we pay specific attention to the potential interactive
effects that may occur from complex mixtures of these compounds in
the environment, proactive steps can be taken in the interim.
Data has been collected on a select number of contaminants.
However, the potential for, and existence of, adverse effects outweigh
the need for continued research without concrete action. Nonhazardous or RCRA hazardous pharmaceuticals that appear in the
drinking and surface water on a national scale should be added to the
Drinking Water Contaminant List. 23 3 While technology to detect
pharmaceuticals at the low concentration levels present in the
environment is still developing, this should not hinder the
implementation of minimum requirements that can be coupled with
the use of existing technology. As the technology advances, the
minimum allowable levels can be amended.

231. Iowa has a statewide pharmaceutical take back program termed
"TakeAway" that encourages pharmacies to receive unused and unwanted products
from consumers. See Take Away Environmental Return System, IOWA PHARMACY
Ass'N, http://www.iarx.org/takeaway/ (last visited April 11, 2011).
232. See discussion supra Part I, Section 1.
233. The EPA conducts research into the contaminants that appear on this list in
order to determine whether regulation is needed. While, they are currently
unregulated by existing national primary drinking water regulations, the EPA
usually chooses from this list when adding contaminants to the National Primary
and Secondary Drinking Water standards. See ENVTL. PROT. AGENCY, DRINKING
WATER

CONTAMINANT

LIST

AND

REGULATORY

http://www.epa.gov/safewater/ccl/basicinformation.html
2009).

DETERMINATIONS,

(last visited Mar.

17,
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4. Ecotoxicity
The FDA considers the environmental impact of all human and
veterinary drug applications unless a categorical exemption
applies.23 4 Indeed, most federal agencies are required to assess the
environmental impact of their proposals under the National
Environmental Policy Act ("NEPA").23 5 Currently, many drug
applications can be granted a categorical exclusion to NEPA and
Center for Drug Evaluation and Research requirements if the
concentration of the substance will be below one part per billion
("ppb") at the time of entry into the environment. 236 A categorical
exclusion cannot be granted if it is established that the substance will
have a significant effect on the quality of the human environment. 237
This then begs the question of whether mutations and spawning
abnormalities in aquatic life significantly affect the quality of the
human environment under NEPA therefore necessitating an
amendment of the one ppb categorical exclusion currently in place.
NEPA's interpretation of the "human environment" is broad and
includes both "the natural and physical environment and the
relationship of people with that environment". 23 8 In addition, NEPA
also interprets "effects" comprehensively considering ecological
effects that impact natural resources and the functioning of
ecosystems.239 It is arguable that the categorical exclusion granted to
234. 21 C.F.R. §§ 21.250 (1), (m) (2010).
235. 42 U.S.C. §§ 4321-4347 (2009).
236. See GARY M. RAND, FUNDAMENTALS OF AQUATIC TOXICOLOGY 736, 74142 (Gary M. Rand ed., 2d ed. 1995); U.S. DEP'T OF HEALTH & HUM. SERVICES,
FOOD

& DRUG

ADMIN., CTR. FOR DRUG EVALUATION

& RES.,

CTR FOR BIOLOGICS

Guidancefor Industry: EnvironmentalAssessment ofHuman
Drug and Biologics Applications, 2 -5 (1998), availableat http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucmO7O
561.pdf,
237. See Cooperation of agencies; reports; availability of information;
recommendations; international and national coordination of efforts, 42 U.S.C. §
4332(2)(c) (2009); 21 C.F.R. § 25.22(b) (2010).
238. See 40 C.F.R. § 1508.14 (2010) ("Human environment shall be interpreted
comprehensively to include the natural and physical environment and the
relationship of people with that environment."); See also 40 C.F.R. §§
1508.27(b)(4), (5) (2010) (discussing the "quality" of the human environment and
"effects" to the human environment).
239. 40 C.F.R. § 1508.8(b) (2010) ("Effects includes ecological (such as the
effects on natural resources and on the components, structures, and functioning of
EVALUATION & RES.,
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pharmaceuticals does significantly affect the quality of the human
environment and that the one ppb standard should be amended.
CONCLUSION

The presence of pharmaceuticals in our waterways can be
addressed with targeted efforts. As many of the ramifications of our
current actions may not be seen for several decades, it is imperative
that we act now to reduce or maintain current levels before we begin
to see serious and significant environmental problems in our
ecosystem.
It is important that states address hospital and veterinary waste
management inefficiencies and ensure that, at a minimum, they
understand and are in compliance with federally mandated standards.
It is also essential that individuals are made aware of the
environmental impact that PPCP use and disposal have on our
nation's water. A system for the collection and proper disposal of
unused pharmaceuticals, an increase in scientific research on these
chemical contaminants, paired with improvements to wastewater
treatment systems, can greatly reduce the prevalence of these
contaminants in our waterways.
Finally, as it is difficult to pinpoint which sources are contributing
the most to this burgeoning PPCP problem, it is necessary that federal
initiatives not only target large facilities, such as hospitals and
pharmacies, but also the general population. Federal Agencies, States
and private organizations alike should launch initiatives that will
raise citizen awareness about the issue.

affected ecosystems), aesthetic, historic, cultural, economic, social, or health,
whether direct, indirect, or cumulative.").

